Helus Pharma completes enrolment in Phase 3 APPROACH depression trial; topline still due Q4 2026
Helus Pharma has enrolled 223 patients in its Phase 3 study of HLP003 in major depressive disorder, while quarterly net loss widened to $103.1M.
Helus Pharma Inc. said on 16 November 2026 that it has completed enrolment in APPROACH, its Phase 3 study of HLP003 as an adjunctive treatment for major depressive disorder (MDD). The study enrolled 223 patients, and the company continues to expect topline data in the fourth quarter of 2026.
Subscribe to keep reading
$4.99 / month
- Every article, analysis and opinion piece on VigiEye and CompePharma
- One subscription for both sites, cancel any time
Already a subscriber? Enter your email below: we'll send you a sign-in link. No password needed.
Company's press release (SEC filing): Helus Pharma Inc. ↗
Article written by VigiEye from the official source (Helus Pharma Inc.). Claims are the company's own. AI-assisted; check the source before acting.